Concepts (321)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 4 | 2020 | 89 | 2.490 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2019 | 14 | 1.950 |
Why?
|
| Neoplasms | 12 | 2024 | 692 | 1.920 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2019 | 11 | 1.730 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 271 | 1.220 |
Why?
|
| Models, Statistical | 4 | 2018 | 173 | 1.090 |
Why?
|
| Prediabetic State | 2 | 2023 | 65 | 1.010 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2015 | 34 | 0.990 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 89 | 0.940 |
Why?
|
| Humans | 62 | 2024 | 32020 | 0.920 |
Why?
|
| Orthopedic Nursing | 2 | 2020 | 4 | 0.910 |
Why?
|
| Preoperative Care | 2 | 2020 | 115 | 0.840 |
Why?
|
| Perception | 2 | 2020 | 98 | 0.820 |
Why?
|
| Treatment Outcome | 9 | 2024 | 3317 | 0.780 |
Why?
|
| Research Design | 5 | 2023 | 312 | 0.750 |
Why?
|
| Cardiovascular Diseases | 3 | 2024 | 1125 | 0.750 |
Why?
|
| Patient Discharge | 2 | 2019 | 188 | 0.750 |
Why?
|
| Nurses | 1 | 2020 | 15 | 0.700 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 20 | 0.670 |
Why?
|
| Tretinoin | 1 | 2019 | 34 | 0.670 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 1428 | 0.670 |
Why?
|
| Statistics as Topic | 1 | 2018 | 108 | 0.610 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 165 | 0.590 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 244 | 0.580 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 409 | 0.580 |
Why?
|
| Medulloblastoma | 1 | 2017 | 7 | 0.580 |
Why?
|
| Cerebellar Neoplasms | 1 | 2017 | 11 | 0.580 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 507 | 0.580 |
Why?
|
| Adult | 23 | 2024 | 9363 | 0.560 |
Why?
|
| Maximum Tolerated Dose | 3 | 2018 | 61 | 0.560 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 607 | 0.550 |
Why?
|
| Vaginal Smears | 2 | 2014 | 9 | 0.550 |
Why?
|
| Female | 33 | 2024 | 19950 | 0.540 |
Why?
|
| Medical Records | 2 | 2013 | 76 | 0.530 |
Why?
|
| Social Work | 2 | 2024 | 8 | 0.530 |
Why?
|
| Middle Aged | 24 | 2024 | 11866 | 0.480 |
Why?
|
| Male | 29 | 2024 | 19193 | 0.460 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2018 | 94 | 0.450 |
Why?
|
| Head and Neck Neoplasms | 3 | 2024 | 130 | 0.450 |
Why?
|
| Young Adult | 10 | 2018 | 2613 | 0.440 |
Why?
|
| Kentucky | 5 | 2015 | 15 | 0.430 |
Why?
|
| Mass Screening | 2 | 2022 | 264 | 0.420 |
Why?
|
| Aging | 4 | 2018 | 945 | 0.410 |
Why?
|
| Lip | 3 | 2017 | 7 | 0.400 |
Why?
|
| Computer Simulation | 4 | 2018 | 221 | 0.400 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 168 | 0.400 |
Why?
|
| Telemedicine | 2 | 2023 | 99 | 0.380 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 216 | 0.380 |
Why?
|
| Patient Compliance | 1 | 2012 | 224 | 0.370 |
Why?
|
| Postural Balance | 2 | 2018 | 182 | 0.370 |
Why?
|
| Quality of Life | 6 | 2024 | 928 | 0.350 |
Why?
|
| Food Supply | 2 | 2011 | 67 | 0.350 |
Why?
|
| Smoking Cessation | 2 | 2023 | 197 | 0.350 |
Why?
|
| Aged | 17 | 2024 | 10338 | 0.350 |
Why?
|
| Adolescent | 9 | 2018 | 3523 | 0.330 |
Why?
|
| Lymphocyte Depletion | 1 | 2018 | 17 | 0.310 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 761 | 0.310 |
Why?
|
| Voice Quality | 2 | 2018 | 6 | 0.300 |
Why?
|
| Laryngeal Neoplasms | 2 | 2017 | 15 | 0.290 |
Why?
|
| Kidney Failure, Chronic | 2 | 2022 | 541 | 0.290 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 124 | 0.290 |
Why?
|
| Guideline Adherence | 2 | 2014 | 119 | 0.280 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 420 | 0.270 |
Why?
|
| United States | 8 | 2024 | 3938 | 0.270 |
Why?
|
| Vibration | 2 | 2015 | 11 | 0.270 |
Why?
|
| Doxorubicin | 2 | 2017 | 82 | 0.270 |
Why?
|
| Appalachian Region | 3 | 2015 | 17 | 0.260 |
Why?
|
| Obesity | 2 | 2023 | 1179 | 0.250 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 154 | 0.240 |
Why?
|
| Touch Perception | 1 | 2014 | 2 | 0.240 |
Why?
|
| Communications Media | 1 | 2024 | 4 | 0.240 |
Why?
|
| Acupuncture Therapy | 1 | 2024 | 19 | 0.240 |
Why?
|
| Xerostomia | 1 | 2024 | 30 | 0.240 |
Why?
|
| Aromatase Inhibitors | 1 | 2013 | 9 | 0.230 |
Why?
|
| Nurse Practitioners | 1 | 2024 | 11 | 0.230 |
Why?
|
| Papillomavirus Infections | 2 | 2015 | 65 | 0.230 |
Why?
|
| Referral and Consultation | 2 | 2017 | 141 | 0.230 |
Why?
|
| Postoperative Complications | 2 | 2021 | 785 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 629 | 0.230 |
Why?
|
| Sirolimus | 1 | 2013 | 33 | 0.230 |
Why?
|
| Needs Assessment | 1 | 2024 | 76 | 0.230 |
Why?
|
| Radiation Injuries | 1 | 2024 | 72 | 0.230 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 2280 | 0.230 |
Why?
|
| Tumor Burden | 1 | 2013 | 60 | 0.230 |
Why?
|
| Gamma Rays | 1 | 2013 | 25 | 0.220 |
Why?
|
| Treatment Failure | 1 | 2013 | 163 | 0.220 |
Why?
|
| Pilot Projects | 5 | 2023 | 544 | 0.220 |
Why?
|
| Radiation Dosage | 1 | 2013 | 81 | 0.220 |
Why?
|
| Pesticides | 1 | 2016 | 200 | 0.220 |
Why?
|
| Estradiol | 1 | 2013 | 128 | 0.220 |
Why?
|
| Tobacco Use Cessation | 1 | 2023 | 19 | 0.220 |
Why?
|
| Risk Factors | 4 | 2024 | 3869 | 0.220 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 45 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 233 | 0.220 |
Why?
|
| Medical Oncology | 4 | 2024 | 84 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 291 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 245 | 0.210 |
Why?
|
| Social Support | 2 | 2024 | 179 | 0.210 |
Why?
|
| Nutritional Status | 1 | 2013 | 75 | 0.210 |
Why?
|
| Caregivers | 1 | 2024 | 113 | 0.210 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1529 | 0.210 |
Why?
|
| Music Therapy | 1 | 2022 | 7 | 0.210 |
Why?
|
| Age Factors | 4 | 2018 | 1194 | 0.200 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 89 | 0.200 |
Why?
|
| Vitamin D | 1 | 2013 | 183 | 0.190 |
Why?
|
| Electric Stimulation Therapy | 1 | 2021 | 14 | 0.190 |
Why?
|
| Muscle Weakness | 1 | 2021 | 37 | 0.190 |
Why?
|
| Overweight | 1 | 2023 | 279 | 0.190 |
Why?
|
| Quadriceps Muscle | 1 | 2021 | 34 | 0.190 |
Why?
|
| Knee Injuries | 1 | 2021 | 42 | 0.180 |
Why?
|
| Geography | 1 | 2010 | 34 | 0.180 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 28 | 0.180 |
Why?
|
| Infant | 3 | 2018 | 1061 | 0.180 |
Why?
|
| Child | 4 | 2023 | 2440 | 0.180 |
Why?
|
| Radiosurgery | 1 | 2013 | 356 | 0.170 |
Why?
|
| Child, Preschool | 3 | 2018 | 1269 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2020 | 166 | 0.170 |
Why?
|
| Interviews as Topic | 1 | 2020 | 263 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 942 | 0.170 |
Why?
|
| Algorithms | 2 | 2018 | 496 | 0.160 |
Why?
|
| Behavior Therapy | 1 | 2019 | 103 | 0.160 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 125 | 0.160 |
Why?
|
| Vaccination | 1 | 2010 | 138 | 0.160 |
Why?
|
| Sample Size | 1 | 2018 | 39 | 0.160 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 470 | 0.160 |
Why?
|
| Muscle Fatigue | 1 | 2018 | 12 | 0.160 |
Why?
|
| Voice Disorders | 1 | 2018 | 4 | 0.160 |
Why?
|
| Brain | 2 | 2017 | 950 | 0.160 |
Why?
|
| Rural Population | 2 | 2015 | 273 | 0.150 |
Why?
|
| Shoulder | 1 | 2018 | 43 | 0.150 |
Why?
|
| Infant, Newborn | 2 | 2018 | 673 | 0.150 |
Why?
|
| Sports Medicine | 1 | 2018 | 22 | 0.150 |
Why?
|
| Cohort Studies | 5 | 2017 | 1831 | 0.150 |
Why?
|
| Probability | 1 | 2018 | 158 | 0.150 |
Why?
|
| Survivors | 3 | 2024 | 159 | 0.150 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 187 | 0.150 |
Why?
|
| Voice Training | 1 | 2017 | 1 | 0.150 |
Why?
|
| Cluster Analysis | 2 | 2012 | 128 | 0.150 |
Why?
|
| Brain Concussion | 1 | 2018 | 62 | 0.150 |
Why?
|
| Adipose Tissue, Brown | 1 | 2017 | 6 | 0.150 |
Why?
|
| Laryngectomy | 1 | 2017 | 3 | 0.150 |
Why?
|
| Muscle Contraction | 1 | 2018 | 114 | 0.150 |
Why?
|
| Patient Readmission | 1 | 2019 | 125 | 0.150 |
Why?
|
| Propranolol | 1 | 2017 | 16 | 0.150 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 638 | 0.150 |
Why?
|
| Vocal Cords | 1 | 2017 | 9 | 0.150 |
Why?
|
| Length of Stay | 1 | 2019 | 318 | 0.150 |
Why?
|
| Athletic Injuries | 1 | 2018 | 82 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 50 | 0.150 |
Why?
|
| Myocytes, Cardiac | 1 | 2017 | 86 | 0.150 |
Why?
|
| Visual Perception | 1 | 2018 | 116 | 0.150 |
Why?
|
| Otolaryngology | 1 | 2017 | 17 | 0.150 |
Why?
|
| Face | 1 | 2017 | 29 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2017 | 30 | 0.140 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 371 | 0.140 |
Why?
|
| Demography | 1 | 2017 | 110 | 0.140 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 159 | 0.140 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 56 | 0.140 |
Why?
|
| Retrospective Studies | 6 | 2018 | 3523 | 0.140 |
Why?
|
| Sensation | 1 | 2017 | 55 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2017 | 134 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 35 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2017 | 116 | 0.140 |
Why?
|
| Stroke | 1 | 2022 | 584 | 0.140 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 163 | 0.140 |
Why?
|
| Glioblastoma | 1 | 2018 | 156 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 101 | 0.130 |
Why?
|
| Muscle, Skeletal | 2 | 2017 | 517 | 0.130 |
Why?
|
| Auditory Threshold | 1 | 2015 | 3 | 0.130 |
Why?
|
| Mesna | 1 | 2015 | 3 | 0.130 |
Why?
|
| Genes, p16 | 1 | 2015 | 1 | 0.130 |
Why?
|
| Protective Agents | 1 | 2015 | 4 | 0.130 |
Why?
|
| SEER Program | 1 | 2015 | 35 | 0.130 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2015 | 48 | 0.130 |
Why?
|
| Carboplatin | 1 | 2015 | 48 | 0.130 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 18 | 0.120 |
Why?
|
| Survival Rate | 3 | 2018 | 885 | 0.120 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 21 | 0.120 |
Why?
|
| Paclitaxel | 1 | 2015 | 67 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 757 | 0.120 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 49 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2015 | 57 | 0.120 |
Why?
|
| Meningioma | 1 | 2015 | 57 | 0.120 |
Why?
|
| Papillomavirus Vaccines | 1 | 2015 | 44 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 324 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 211 | 0.120 |
Why?
|
| Sigmoidoscopy | 1 | 2013 | 3 | 0.120 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2024 | 19 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2013 | 18 | 0.110 |
Why?
|
| Colonoscopy | 1 | 2013 | 45 | 0.110 |
Why?
|
| Community-Based Participatory Research | 1 | 2014 | 114 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 4000 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2013 | 186 | 0.110 |
Why?
|
| Hospitals, Public | 1 | 2012 | 5 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2014 | 122 | 0.110 |
Why?
|
| Rural Health Services | 1 | 2012 | 30 | 0.110 |
Why?
|
| Time Factors | 1 | 2018 | 2152 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 69 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 353 | 0.100 |
Why?
|
| Restaurants | 2 | 2011 | 7 | 0.090 |
Why?
|
| Lung | 2 | 2023 | 255 | 0.090 |
Why?
|
| Radiotherapy | 2 | 2024 | 82 | 0.090 |
Why?
|
| Single-Blind Method | 2 | 2022 | 202 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2018 | 897 | 0.090 |
Why?
|
| Hypertension | 1 | 2017 | 957 | 0.090 |
Why?
|
| Renal Dialysis | 2 | 2022 | 279 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 899 | 0.080 |
Why?
|
| Depression | 2 | 2023 | 442 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 319 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 461 | 0.070 |
Why?
|
| Blood Pressure | 2 | 2024 | 845 | 0.070 |
Why?
|
| Comorbidity | 1 | 2018 | 569 | 0.070 |
Why?
|
| Population Surveillance | 2 | 2018 | 125 | 0.070 |
Why?
|
| Oxidation-Reduction | 2 | 2017 | 268 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2018 | 488 | 0.060 |
Why?
|
| Cancer Care Facilities | 1 | 2024 | 10 | 0.060 |
Why?
|
| Sensory Thresholds | 1 | 2014 | 28 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 878 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 39 | 0.060 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 103 | 0.060 |
Why?
|
| Health Services Needs and Demand | 1 | 2024 | 81 | 0.060 |
Why?
|
| Micronutrients | 1 | 2013 | 18 | 0.050 |
Why?
|
| Dyspnea | 1 | 2023 | 32 | 0.050 |
Why?
|
| Glucose | 1 | 2024 | 174 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2024 | 147 | 0.050 |
Why?
|
| Communication | 1 | 2024 | 140 | 0.050 |
Why?
|
| Patient Participation | 1 | 2023 | 82 | 0.050 |
Why?
|
| Walking | 1 | 2023 | 210 | 0.050 |
Why?
|
| Medicare | 1 | 2024 | 207 | 0.050 |
Why?
|
| Cholesterol | 1 | 2024 | 251 | 0.050 |
Why?
|
| Urban Population | 1 | 2013 | 89 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 239 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 300 | 0.050 |
Why?
|
| Urea | 1 | 2021 | 37 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 292 | 0.050 |
Why?
|
| Affect | 1 | 2022 | 69 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2013 | 474 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2017 | 2281 | 0.050 |
Why?
|
| Health Status | 1 | 2024 | 399 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1516 | 0.050 |
Why?
|
| Food Industry | 1 | 2011 | 9 | 0.050 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 18 | 0.050 |
Why?
|
| Anxiety | 1 | 2023 | 188 | 0.050 |
Why?
|
| South Carolina | 1 | 2011 | 31 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2012 | 136 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 370 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2023 | 270 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 305 | 0.050 |
Why?
|
| Population Density | 1 | 2010 | 8 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2010 | 45 | 0.050 |
Why?
|
| Logistic Models | 1 | 2013 | 781 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2021 | 161 | 0.040 |
Why?
|
| Prevalence | 1 | 2013 | 981 | 0.040 |
Why?
|
| Data Collection | 1 | 2010 | 180 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2013 | 923 | 0.040 |
Why?
|
| Proprioception | 1 | 2018 | 6 | 0.040 |
Why?
|
| Torque | 1 | 2018 | 20 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 480 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 57 | 0.040 |
Why?
|
| Smoking | 1 | 2022 | 500 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2018 | 70 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2024 | 1435 | 0.040 |
Why?
|
| Aldehydes | 1 | 2017 | 5 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2017 | 33 | 0.040 |
Why?
|
| Athletes | 1 | 2018 | 69 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2017 | 46 | 0.040 |
Why?
|
| Stroboscopy | 1 | 2017 | 1 | 0.040 |
Why?
|
| Proteome | 1 | 2017 | 39 | 0.040 |
Why?
|
| Speech Disorders | 1 | 2017 | 6 | 0.040 |
Why?
|
| Speech Acoustics | 1 | 2017 | 4 | 0.040 |
Why?
|
| Speech | 1 | 2017 | 9 | 0.040 |
Why?
|
| Kinetics | 1 | 2017 | 209 | 0.040 |
Why?
|
| Pulmonary Ventilation | 1 | 2017 | 14 | 0.040 |
Why?
|
| Larynx | 1 | 2017 | 20 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 407 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 126 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 170 | 0.040 |
Why?
|
| Proteomics | 1 | 2017 | 94 | 0.040 |
Why?
|
| Fever | 1 | 2017 | 61 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 194 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 355 | 0.030 |
Why?
|
| Auditory Perception | 1 | 2017 | 80 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 73 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 565 | 0.030 |
Why?
|
| Shoulder Joint | 1 | 2018 | 126 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 765 | 0.030 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2017 | 198 | 0.030 |
Why?
|
| Legislation as Topic | 1 | 2015 | 5 | 0.030 |
Why?
|
| Interleukin-18 | 1 | 2015 | 9 | 0.030 |
Why?
|
| Solubility | 1 | 2015 | 37 | 0.030 |
Why?
|
| Physical Stimulation | 1 | 2015 | 84 | 0.030 |
Why?
|
| Heart Rate | 1 | 2017 | 334 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2015 | 79 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 771 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 84 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 22 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 24 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 78 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 93 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 13 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 766 | 0.030 |
Why?
|
| Immunization Schedule | 1 | 2015 | 26 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2015 | 37 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 151 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 492 | 0.030 |
Why?
|
| Liver | 1 | 2017 | 483 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 265 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 260 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 1017 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 323 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 456 | 0.030 |
Why?
|
| Registries | 1 | 2015 | 298 | 0.030 |
Why?
|
| Women's Health | 1 | 2015 | 236 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 1505 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 242 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2015 | 384 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1200 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 2475 | 0.020 |
Why?
|
| African Americans | 1 | 2015 | 1428 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 7466 | 0.020 |
Why?
|